ARC Group Announces Successful IPO of Gelteq Limited on Nasdaq

ARC Group Announces Successful IPO of Gelteq Limited on Nasdaq

ARC Group is pleased to announce its role as the financial advisor to Gelteq Limited (“Gelteq”), a pioneering biotechnology firm, in its initial public (IPO) offering on Nasdaq. Gelteq has priced its IPO of 1,300,000 ordinary shares at US$4.00 per share, yielding gross proceeds of US $5.2 million. Trading commenced yesterday on Nasdaq on October 29, 2024, under the ticker symbol “GELS.”

About Gelteq Limited

Gelteq, based in Melbourne, Australia, specializes in the development of ingestible gel technology designed to improve the delivery of nutrients and pharmaceuticals. The funds raised will support the Company’s continued investment in manufacturing, marketing, and R&D initiatives aimed at advancing its innovative gel-based delivery solutions across key industries, including pharmaceuticals, nutraceuticals as well as animal health.

“This IPO marks an exciting milestone for Gelteq as it enters the global public markets. It has been an honor to work alongside Gelteq’s team, and we are thrilled to have supported them in reaching this significant achievement,” said Jesús Hoyos, Managing Partner at ARC Group. “Gelteq’s platform has the potential to revolutionize drug delivery systems, and we look forward to seeing the Company’s continued success as it scales.”

ARC Group is proud to have served as Gelteq’s financial advisor in this transaction.

Jesús Hoyos, Managing Partner at ARC Group, added, “This transaction highlights the value ARC Group brings to emerging growth companies seeking access to international capital markets. Gelteq is at the forefront of its field, and we are proud to have been part of their journey to Nasdaq.”

About ARC Group

ARC Group is a globally based, full-service financial institution, specializing in bridging Asia and the West. Our services encompass a full spectrum of financial solutions, including IPOs, M&A, financing, venture capital, and SPACs. ARC Group also includes an independent consulting division dedicated to addressing the unique challenges faced by companies operating across both Asian and Western markets. Headquartered in Hong Kong, with offices across Mainland China, the USA, Malaysia, Indonesia, Vietnam, India, Sweden, and the UAE, we are well-positioned to provide cross-border financial and advisory services.

Our commitment to anticipating market trends and delivering client-centered solutions has earned ARC Group the Frost & Sullivan 2024 Company of the Year Award in the Asian mid-market investment advisory sector.

For more information or any questions, please contact:

Jesús Hoyos
Managing Partner
[email protected]

For media inquiries, please contact:

Anna Sahlberg Carlsson
Marketing Manager
[email protected]

Ready to talk to one of our experts?

Contact us here for all your capital markets and M&A needs.

Not quite ready for an IPO yet? Our consulting division is here to help you prepare for the future.

Get in touch to explore how we can support your growth journey.

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission